51 research outputs found
Psycholog biznesu w percepcji menedżerów średniego szczebla
The aim of this article is to present the way of cooperation between psychologists and people working in business. The article explains how mid-level managers perceive them. The results of our research will show two types of psychologist working in business – ordinary one and ideal one. Second of type is considered as perfect image of a business psychologist which is the most coveted by managers. The outcome will let to describe main features which are the most required from psychologist in this specific sector of business. The research tool was a questionnaire containing two types of questions: semantic differential and ranking. First part of research shows that in accordance to managers, the most desirable features are responsibility and empathy. The actual examination included 43 managers working in several Polish provinces. We reckon that the results of the academic research will update the knowledge about the current expectations of entrepreneurs for psychologists.Celem artykułu jest przedstawienie, w jaki sposób psychologowie współpracujący ze środowiskiem biznesowym są spostrzegani przez menedżerów średniego szczebla. Na podstawie wyników badań własnych przedstawiony zostanie przeciętny obraz psychologa biznesu, a także obraz idealny, oparty na charakterystykach najbardziej pożądanych zdaniem kadry zarządzającej. Wyniki badań pozwolą na ustalenie, jakie cechy powinni posiadać psychologowie współpracujący ze środowiskiem biznesowym. Narzędzie badawcze stanowił kwestionariusz ankiety, zwierający pytania w formie dyferencjału semantycznego i rangowania. Badania rozpoczęły się pilotażem (N = 17), który wykazał m.in., iż zdaniem menedżerów, najbardziej pożądanymi cechami psychologa biznesu są odpowiedzialność oraz empatia. Badanie właściwe objęło 43 menedżerów, pracujących na terenie kilku polskich województw. Sądzimy, iż wyniki badania pozwolą środowisku akademickiemu zaktualizować wiedzę na temat obecnych oczekiwań przedsiębiorców wobec psychologów
Evaluation of Expression of the PTEN Gene, Oestrogen and Progesterone Receptors as Diagnostic and Predictive Factors in Endometrial Cancer
Endometrial cancer belongs to the commonest malignancy in females after breast cancer, malignant neoplasm of female genitals in Europe and North America but there is still not significant improvement as far as the curability of this neoplasm is concerned, especially its advanced forms. That is why there is need to define new factors that could be not only diagnostic but also predictve factors. In present study we analyzed the mRNA PTEN expression by quantitative real-time polymerase chain reaction (Q-PCR) in 123 women of endometrial carcinoma and 14 women of control group. Moreover we assessed oestrogen (ER) and progesterone receptors (PgR) in all cases. We defined the correlation between expression of PTEN gene and receptors and between PTEN expression and maturity grade of cancer. Neoplasm advancement grade G1 was diagnosed in 82.11 % of patients (n = 101), G2 in 9.76 % of patients (n = 12) and G3 in 8.13 % of patients (n = 10). Presence of ER and PgR and decreased expression of PTEN gene was found in majority of patients with endometrial cancer (79.12 % and 59.34 % respectively) and the most numerous group was with weak expression of ER and strong expression of PgR. There was no statistically significant difference in gene expression depending on receptors expression nor maturity grade of cancer (p > 0.05). Evaluation of expression of PTEN gene may turn out to be a very useful tool aimed at qualifying patients for different therapies of endometrial cancer and at searching of new diagnostic and therapeutic methods of this cancer independently on its receptor status nor maturity grade of cancer
Novel sulfoglycolipid IG20 causes neuroprotection by activating the phase II antioxidant response in rat hippocampal slices
Los datos de investigación asociados a este artículo están disponibles en http://dx.doi.org/10.1016/j.neuropharm.2016.12.016Compound IG20 is a newly synthesised sulphated glycolipid that promotes neuritic outgrowth and myelinisation, at the time it causes the inhibition of glial proliferation and facilitates exocytosis in chromaffin cells. Here we have shown that IG20 at 0.3–10 μM afforded neuroprotection in rat hippocampal slices stressed with veratridine, glutamate or with oxygen plus glucose deprivation followed by reoxygenation (OGD/reox). Excess production of reactive oxygen species (ROS) elicited by glutamate or ODG/reox was prevented by IG20 that also restored the depressed tissue levels of GSH and ATP in hippocampal slices subjected to OGD/reox. Furthermore, the augmented iNOS expression produced upon OGD/reox exposure was also counteracted by IG20. Additionally, the IG20 elicited neuroprotection was prevented by the presence of inhibitors of the signalling pathways Jak2/STAT3, MEK/ERK1/2, and PI3K/Akt, consistent with the ability of the compound to increase the phosphorylation of Jak2, ERK1/2, and Akt. Thus, the activation of phase II response and the Nrf2/ARE pathway could explain the antioxidant and anti-inflammatory effects and the ensuing neuroprotective actions of IG20This study was supported by a grant from Ministerio de Economía
y Competitividad, Spain (MINECO SAF2013-44108-P to AGG
and LG; MAT2015-65184-C2-2-R to AFM, CABICYC UAM-Bioiberica
and European Commission-ERC, People (Marie Curie Actions) FP7
under REA grant agreement n PCIG11-GA-2012-322156; Spanish
Ministry of Health (Instituto de Salud Carlos III) (grant PI14/00372)
and Miguel Servet (CP11/00165); Bayer A.G., “From Targets to Novel
Drugs” program (grant 2015-03-1282) and Fundacion FIPSE (grant
12-00001344-15) to RL. RL thanks IS Carlos III for research contract
under Miguel Servet Program. P.M. thanks MECD for FPU fellowship
(AP2010-1219
Enantioselective Synthesis and Pharmacological Evaluation of Aza-CGP37157–Lipoic Acid Hybrids for the Treatment of Alzheimer’s Disease
Hybrids based on an aza-analogue of CGP37157, a mitochondrial Na+/Ca2+ exchanger antagonist, and lipoic acid were obtained in order to combine in a single molecule the antioxidant and NRF2 induction properties of lipoic acid and the neuroprotective activity of CGP37157. The four possible enantiomers of the hybrid structure were synthesized by using as the key step a fully diastereoselective reduction induced by Ellman’s chiral auxiliary. After computational druggability studies that predicted good ADME profiles and blood–brain permeation for all compounds, the DPPH assay showed moderate oxidant scavenger capacity. Following a cytotoxicity evaluation that proved the compounds to be non-neurotoxic at the concentrations tested, they were assayed for NRF2 induction capacity and for anti-inflammatory properties and measured by their ability to inhibit nitrite production in the lipopolysaccharide-stimulated BV2 microglial cell model. Moreover, the compounds were studied for their neuroprotective effect in a model of oxidative stress achieved by treatment of SH-SY5Y neuroblastoma cells with the rotenone–oligomycin combination and also in a model of hyperphosphorylation induced by treatment with okadaic acid. The stereocenter configuration showed a critical influence in NRF2 induction properties, and also in the neuroprotection against oxidative stress experiment, leading to the identification of the compound with S and R configuration as an interesting hit with a good neuroprotective profile against oxidative stress and hyperphosphorylation, together with a relevant anti-neuroinflammatory activity. This interesting multitarget profile will be further characterized in future work
The angiotensin-(1-7)/Mas receptor a xis protects from endothelial cell senescence via klotho and Nrf2 activation
Endothelial cell senescence is a hallmark of va
scular aging that pre
disposes to vascular
disease. We aimed to explore the capacity of the renin-angiotensin system (RAS)
heptapeptide angiotensin (Ang)-(1-7)
to counteract human endothelial cell senescence
and to identify intracellular pathways mediati
ng its potential protective action. In human
umbilical vein endothelial cell (HUVEC) cult
ures, Ang II promoted cell senescence, as
revealed by the enhancement in se
nescence-associated galactosidase (SA-
-gal+)
positive staining, total and telomeric DNA
damage, adhesion molecules expression and
human mononuclear adhesion to HUVEC monolaye
rs. By activating the G-coupled
receptor Mas, Ang-(1-7) inhibit
ed the pro-senescence action
of Ang II, but also of a non-
RAS stressor such as the cytokine IL-1
. Moreover, Ang-(1-7) enhanced endothelial
klotho levels, while klotho silencing resulted in th
e loss of the anti-senescence action of
the heptapeptide. Indeed, both Ang-(1-7) and recombinant klotho activated the
cytoprotective Nrf2/heme-oxygenase-1 (HO)-1 pathway. The HO-1 inhibitor tin
protoporphyrin IX prevented the anti-senescence action evoked by Ang-(1-7) or
recombinant klotho. Overall, the present study ide
ntifies Ang-(1-7) as an anti-senescence
peptide displaying its protectiv
e action beyond the RAS by consecutively activating
klotho and Nrf2/HO-1. Ang-(1-7) mimetic dru
gs may thus prove useful to prevent
endothelial cell senescence and its re
lated vascular complications
New Nrf2-Inducer Compound ITH12674 Slows the Progression of Retinitis Pigmentosa in the Mouse Model rd10
Background/Aims: It is well established that oxidative stress and inflammation are common pathogenic features of retinal degenerative diseases. ITH12674 is a novel compound that induces the transcription factor Nrf2; in so doing, the molecule exhibits anti-inflammatory, and antioxidant properties, and affords neuroprotection in rat cortical neurons subjected to oxidative stress. We here tested the hypothesis that ITH12674 could slow the retinal degeneration that causes blindness in rd10 mice, a model of retinitis pigmentosa. Methods: Animals were intraperitoneally treated with 1 or 10 mg/Kg ITH12674 or placebo from P16 to P30. At P30, retinal functionality and visual acuity were analyzed by electroretinography and optomotor test. By immunohistochemistry we quantified the photoreceptor rows and analyzed their morphology and connectivity. Oxidative stress and inflammatory state was studied by Western blot, and microglia reactivity was monitored by flow cytometry. The blood−brain barrier permeation of ITH12674 was evaluated using a PAMPA-BBB assay. Results: In rd10 mice treated with 10 mg/Kg of the compound, the following changes were observed (with respect to placebo): (i) a decrease of vision loss with higher scotopic a- and b-waves; (ii) increased visual acuity; (iii) preservation of cone photoreceptors morphology, as well as their synaptic connectivity; (iv) reduced expression of TNF-α and NF-κB; (v) increased expression of p38 MAPK and Atg12-Atg5 complex; and (vi) decreased CD11c, MHC class II and CD169 positive cell populations. Conclusion: These data support the view that a Nrf2 inducer compound may arise as a new therapeutic strategy to combat retinal neurodegeneration. At present, we are chemically optimising compound ITH12674 with the focus on improving its neuroprotective potential in retinal neurodegenerative diseases.This work was supported by grants from Bayer (Grats4Targets), from the Spanish Ministry of Economy and Competitiveness (MINECO-FEDER BFU2015-67139-R), Spanish Ministry of Education (FPU14/03166, FPU13/03737 and FPU16/04114), Instituto de Salud Carlos III co-financed by the European Regional Development’s funds (FEDER) (RETICS-FEDER RD16/0008/0016, Programa Miguel Servet II (CP16/00014) and research project (grant PI17/01700)), Asociación Retina Asturias, Fundación La Caixa, CaixaImpulse program (grant CI17-00048), Comunidad Autónoma de Madrid (grant B2017/BMD-3827), Generalitat Valenciana (PROMETEO/2016/158 and ACIF/2016/055) Generalitat Valenciana-FEDER IDIFEDER/2017/064
MAFG is a potential therapeutic target to restore chemosensitivity in cisplatin-resistant cancer cells by increasing reactive oxygen species
Adjuvant chemotherapy for solid tumors based on platinum-derived compounds such as cisplatin is the treatment of choice in most cases. Cisplatin triggers signaling pathways that lead to cell death, but it also induces changes in tumor cells that modify the therapeutic response, thereby leading to cisplatin resistance. We have recently reported that microRNA-7 is silenced by DNA methylation and is involved in the resistance to platinum in cancer cells through the action of the musculoaponeurotic fibrosarcoma oncogene family, protein G (MAFG). In the present study, we first confirm the miR-7 epigenetic regulation of MAFG in 44 normal- and/or tumor-paired samples in non–small-cell lung cancer (NSCLC). We also provide translational evidence of the role of MAFG and the clinical outcome in NSCLC by the interrogation of two extensive in silico databases of 2019 patients. Moreover, we propose that MAFG-mediated resistance could be conferred due to lower reactive oxygen species production after cisplatin exposure. We developed specifically selected aptamers against MAFG, with high sensitivity to detect the protein at a nuclear level probed by aptacytochemistry and histochemistry analyses. The inhibition of MAFG activity through the action of the specific aptamer apMAFG6F increased the levels of reactive oxygen species production and the sensitivity to cisplatin. We report first the specific nuclear identification of MAFG as a novel detection method for diagnosis in NSCLC, and then we report that MAFG modulates the redox response and confers cell protection against free radicals generated after platinum administration, thus also being a promising therapeutic target.This study was supported by the “Fondo de Investigación Sanitaria-Instituto de Salud Carlos III” [PI15/00186 and CP 08/000689 to I.I.C. ] ; and the European Regional Development Fund/European Social Fund FIS [FEDER/FSE, Una Manera de Hacer Europa] . MINECO funds support O.V., C.R.A. and O.P.contracts through RTC-2015-4362-1 and RTC-2016-5314-1 projects
Bisavenathramide Analogues as Nrf2 Inductors and Neuroprotectors in In Vitro Models of Oxidative Stress and Hyperphosphorylation
Oxidative stress is crucial to the outbreak and advancement of neurodegenerative diseases and is a common factor to many of them. We describe the synthesis of a library of derivatives of the 4-arylmethylen-2-pyrrolin-5-one framework by sequential application of a three-component reaction of primary amines, β-dicarbonyl compounds, and α-haloketones and a Knoevenagel condensation. These compounds can be viewed as cyclic amides of caffeic and ferulic acids, and are also structurally related to the bisavenanthramide family of natural antioxidants. Most members of the library showed low cytotoxicity and good activity as inductors of Nrf2, a transcription factor that acts as the master regulator of the antioxidant response associated with activation of the antioxidant response element (ARE). Nrf2-dependent protein expression was also proved by the significant increase in the levels of the HMOX1 and NQO1 proteins. Some compounds exerted neuroprotective properties in oxidative stress situations, such as rotenone/oligomycin-induced toxicity, and also against protein hyperphosphorylation induced by the phosphatase inhibitor okadaic acid. Compound 3i, which can be considered a good candidate for further hit-to-lead development against neurodegenerative diseases due to its well-balanced multitarget profile, was further characterized by proving its ability to reduce phosphorylated Tau levels
- …